Share
468 Posts.
lightbulb Created with Sketch. 216
clock Created with Sketch. 08/09/20
10:20
Share
Originally posted by RBx:
↑
From the announcement on 1 September:A range of doses of Veyonda® will be administered to patients hospitalised with moderate symptoms who are at high risk of tipping over into a cytokine storm and developing septic shock. Typically, these patients are sick enough to require hospitalisation, but do not yet have such severe symptoms that they require ICU care or mechanical ventilation. The safety and tolerability of the medication in patients with poor lung function will be measured, as well as the drug’s ability to prevent patients progressing into a cytokine storm and septic shock. One of the key endpoints is the effect of treatment on blood cytokine levels, which will be assayed in an Australian laboratory. Noxopharm remains in discussion with the U.S. FDA on conducting a clinical study in the U.S., with NOXCOVID-1 serving as a pilot, proof-of-principle study.
Expand
Not sure it’s inconceivable, in fact with recovery trial confirming dexa benefit in hospitalised c19 and nih recommends dexa in c19 needing o2 (or MV) it could be deemed unethical to withhold steroids in the group in Nox trial..sounds like at least pts in nox trial are bad enough to need o2?
